FRAT2 CRISPR/Cas9 KO Plasmid (h): sc-406802
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- FRAT2 CRISPR/Cas9 Knockout (KO) Plasmid (h) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the FRAT2 genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
FRAT2 CRISPR/Cas9 KO Plasmid (h) | sc-406802 | 20 µg | $397.00 |
Overview
FRAT2 (Frequently rearranged in advanced T-cell lymphomas 2) encodes a cytoplasmic protein that modulates canonical Wnt/β-catenin signaling by interacting with GSK3β and influencing β-catenin stability and downstream transcriptional programs. Through this pathway, FRAT2 contributes to regulation of cell proliferation, differentiation, and developmental patterning, and can intersect with broader signaling networks that control cell cycle progression and fate decisions. Altered Wnt pathway activity is implicated across multiple disease contexts, including oncogenic transformation and tissue remodeling, making FRAT2 a useful node for dissecting β-catenin–dependent gene expression. Functional interrogation of FRAT2 supports mechanistic studies of pathway crosstalk and context-specific regulation in human cell systems.
FRAT2 CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the FRAT2 gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the FRAT2 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the FRAT2 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish FRAT2 protein expression.
This CRISPR knockout system enables efficient generation of FRAT2-deficient cell models for investigation of FRAT2 signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting FRAT2 exon(s) critical for FRAT2 function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple FRAT2 genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by FRAT2 CRISPR/Cas9 KO Plasmid (h) and FRAT2 CRISPR/Cas9 KO Plasmid (h2) target distinct sites within the FRAT2 locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by FRAT2 HDR Plasmid (h) and FRAT2 HDR Plasmid (h2) contain a puromycin resistance cassette and an RFP reporter flanked by FRAT2 homology arms to support homology-directed repair at defined FRAT2 target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.